You can buy or sell ALXN and other stocks, options, ETFs, and crypto commission-free!
Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Read More Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.
52 Week High
52 Week Low
Why Is Alexion Down 6.3% Since Last Earnings Report?
It has been about a month since the last earnings report for Alexion Pharmaceuticals (ALXN). Shares have lost about 6.3% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Alexion due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Alexion Q1 Earnings Beat Estimates, ...
Alexion Pharmaceuticals Inc.
The U.S. Justice Department said Thursday that Jazz Pharmaceuticals PLC , Alexion Pharmaceuticals Inc. and Lundbeck LLC have agreed to pay a combined $122.6 million to settle allegations that they paid kickbacks through co-pay assistance foundations for their own products. The companies violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical Program (ChampVA) copays for their own products, through purportedly independent foundations that the companies used as conduits, ...
IB TimesMay 19
Top 5 New Drug Launches Of 2019 -- And The Biotech Stocks That Could Win Big
Every year, biopharmaceutical companies introduce new drugs to the market. Some of these drugs become big winners. Others don't. Market research company EvaluatePharma analyzed all of the drugs that could launch in 2019. The company then projected how much each drug could potentially generate by 2024. Alexion Pharmaceuticals (NASDAQ:ALXN), AbbVie (NYSE:ABBV), Aimmune Therapeutics (NASDAQ:AIMT), and bluebird bio (NASDAQ:BLUE) came out on top in EvaluatePharma's ranking of the top five new drug launches expe...
Expected Jul 25, Pre-Market